Focusing downstream in lung cancer prevention: 15-hydroxyprostaglandin dehydrogenase.
Dubinett
Steven M
SM
Division of Pulmonary and Critical Care Medicine, UCLA Lung Cancer Research Program, Johnsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095-1690, USA. sdubinett@mednet.ucla.edu
Mao
Jenny T
JT
Hazra
Saswati
S
D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control*; D018890:Chemoprevention / Q000379:methods*; D051546:Cyclooxygenase 2 / Q000502:physiology; D016503:Drug Delivery Systems; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D016147:Genes, Tumor Suppressor / Q000502:physiology; D006801:Humans; D006911:Hydroxyprostaglandin Dehydrogenases / Q000235:genetics* / Q000502:physiology; D008175:Lung Neoplasms / Q000201:enzymology / Q000517:prevention & control*; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use
D045162:Thiazolidinediones; D006911:Hydroxyprostaglandin Dehydrogenases; C035859:15-hydroxyprostaglandin dehydrogenase; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human